A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.

Autor: Jazaeri A; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America. Electronic address: aajazaeri@mdanderson.org., Coleman RL; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Frumovitz MM; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Soliman PT; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Shafer A; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Cutrera JJ; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Klinger M; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Sharafi SE; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Johnson CAL; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Villanueva VF; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Hinchcliff EM; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Dickens A; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Cain KE; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Anderson JE; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Lu KH; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America., Westin SN; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2018 Nov; Vol. 151 (2), pp. 374-380. Date of Electronic Publication: 2018 Sep 10.